Search

The tolerability and efficacy of epidermal growth factor (EGF) in the topical treatment of herpetic corneal ulcers in addition to topical acyclovir have been evaluated in a double-blind, placebo-controlled, randomized study in two groups of patients. The time required for complete reepithelialization of the cornea was recorded, and the data obtained were analyzed statistically. In the EGF group, the reepithelialization was significantly faster than in the control group. Tolerability of EGF was always excellent. These results indicate that EGF is safe and effective in reducing the healing time of herpetic corneal ulcers.

The tolerability and efficacy of epidermal growth factor (EGF) in the topical treatment of traumatic corneal ulcers have been evaluated in a double-blind, placebo-controlled, randomized study in two groups of patients. The time required for complete reepithelialization of the cornea was recorded, and the data obtained were analyzed statistically. In the EGF group the reepithelialization was significantly faster than in the control group. Tolerability of EGF was always excellent. These results indicate that EGF is safe and effective in reducing the healing time in the management of superficial corneal lesions.

Epidermal growth factor is a protein which stimulates epithelial cell growth. We conducted a randomized double blind study between patients treated with PHZ102 (Inpharzam SA, Cadempino, Switzerland) containing EGF, and placebo eyedrops as topical treatment following epikeratoplasty, to evaluate the effect of EGF on corneal reepithelialization. The patients of the EGF group recovered earlier (1 to 4 days) than the patients in the placebo group (3 to 15 days). Therefore, the results obtained confirmed that EGF may reduce the time normally required for complete reepithelialization of the cornea.